Oligonucleotide Therapy Market Size, Share, and Trends Report by Product Category

 Save 20% on All Global Market Reports With Code ONLINE20 — Gain Insights Into Tariffs, Inflation, and Industry Trends

 

 What Is the Current Market Size and Growth Rate of the Oligonucleotide Therapy Market?
 The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $5.61 billion in 2024 to $6.2 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to growth in investment in research and development, market entry of early therapies, rise of gene editing techniques, early therapeutic discoveries, rnai and antisense oligonucleotide introduction.
 
 The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $9.66 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to research and development investments, global market penetration, therapeutic area expansion, disease modification strategies, regulatory adaptations. Major trends in the forecast period include customized therapies, advancements in delivery systems, rna interference (RNAI) advancements, antisense oligonucleotide innovation, gene editing techniques integration.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=3398&type=smp
 
 What Are the Key Drivers of the Oligonucleotide Therapy Market?
 The rise in the number of cancer cases across the globe is likely to contribute to the growth of the oligonucleotide therapy market during the forecast period. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the oligonucleotide therapy market over the forthcoming years.
 
 How Is the Oligonucleotide Therapy Market Segmented?
 The oligonucleotide therapy market covered in this report is segmented — 
 
 1) By Type: Antisense Oligonucleotide, Aptamer, Other Types
 2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User
 3) By End User: Hospitals, Research Institutes
 
 Subsegments: 
 1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides, DNA-Targeted Antisense Oligonucleotides, Chemically Modified Antisense Oligonucleotides 
 2) By Aptamer: DNA Aptamers, RNA Aptamers, Small Molecule Aptamers 
 3) By Other Types: siRNA (Small Interfering RNA), miRNA (Micro RNA), DNAzyme And Ribozymes, Synthetic Oligonucleotides For Gene Editing 
 
 What Are the Key Trends Shaping the Oligonucleotide Therapy Market?
 The developers and providers of the oligonucleotide therapy market are investing in research and development to remodel the design of therapy to reduce its side effects on patients. The new and innovative oligonucleotides allow for precision medicine approaches and can be designed to selectively target any gene with minimal side effects. It also helps in targeting patient-specific sequences that are causative of rare diseases. In April 2023, the FDA approved Qalsody, an antisense oligonucleotide (ASO), for the treatment of patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. Qalsody targets SOD1 mRNA to reduce the synthesis of SOD1 protein 
 
 Which Are the Top Companies in the Oligonucleotide Therapy Market?
 Major companies operating in the oligonucleotide therapy market include Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Gilead Sciences Inc., BioNTech SE, Moderna Inc., Biogen Inc., Jazz Pharmaceuticals plc, QIAGEN Company, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Dynacure S.A., Arcturus Therapeutics Holdings Inc., Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., Editas Medicine Inc., Evox Therapeutics Ltd., PepGen Ltd. 
 
 Get the full oligonucleotide therapy market report here:
 https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report
 
 Which Region Is Projected to Account for the Largest Share of the Oligonucleotide Therapy Market?
 North America was the largest region in the oligonucleotide therapy market in 2024. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company